Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Vanda Pharmaceuticals (VNDA) Equity Ratio (2016 - 2025)

Vanda Pharmaceuticals' Equity Ratio history spans 16 years, with the latest figure at 0.67 for Q4 2025.

  • For Q4 2025, Equity Ratio fell 18.46% year-over-year to 0.67; the TTM value through Dec 2025 reached 0.67, down 18.46%, while the annual FY2025 figure was 0.67, 18.46% down from the prior year.
  • Equity Ratio for Q4 2025 was 0.67 at Vanda Pharmaceuticals, down from 0.78 in the prior quarter.
  • Across five years, Equity Ratio topped out at 0.86 in Q1 2021 and bottomed at 0.67 in Q4 2025.
  • The 5-year median for Equity Ratio is 0.83 (2024), against an average of 0.82.
  • The largest annual shift saw Equity Ratio rose 2.07% in 2023 before it fell 18.46% in 2025.
  • A 5-year view of Equity Ratio shows it stood at 0.85 in 2021, then dropped by 2.25% to 0.83 in 2022, then grew by 1.1% to 0.84 in 2023, then dropped by 2.34% to 0.82 in 2024, then decreased by 18.46% to 0.67 in 2025.
  • Per Business Quant, the three most recent readings for VNDA's Equity Ratio are 0.67 (Q4 2025), 0.78 (Q2 2025), and 0.81 (Q1 2025).